Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1314893

AstraZeneca PLC (AZN) - Financial and Strategic SWOT Analysis Review

Description:
AstraZeneca PLC (AZN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company that carries out designing, developing, production and marketing of various range of biologics, prescription pharmaceuticals and vaccines for the treatment of diseases such as cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. It offers a wide portfolio of products in various therapeutic areas, some of which include Crestor, Seroquel, Arimidex, Nexium and Symbicort. Its research and development activities focus on the development of pharmaceutical products for certain indications such as type 2 diabetes, infection, COPD, cancer, Alzheimer's disease and others.

AstraZeneca PLC Key Recent Developments

Apr 07, 2014: Starpharma expands its Drug Delivery Program with AstraZeneca
Mar 31, 2014: AstraZeneca and MRC enter strategic collaboration to create new centre for early drug discovery in Cambridge, UK
Mar 28, 2014: Pfizer Statement on U.S. FDA Approval of Over-the-Counter Nexium 24HR
Mar 13, 2014: Medimmune, MD Anderson Join Forces to Advance Cancer Immunotherapy
Mar 11, 2014: AstraZeneca announces sale of Alderley Park site in Cheshire, UK

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
 
Contents:
Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 - About the Company
AstraZeneca PLC - Key Facts
AstraZeneca PLC - Key Employees
AstraZeneca PLC - Key Employee Biographies
AstraZeneca PLC - Major Products and Services
AstraZeneca PLC - Pharmaceutical Pipeline Products Data
AstraZeneca PLC, Pipeline Products by Therapy Area
AstraZeneca PLC, Pipeline Products by Development Phase
AstraZeneca PLC - History
AstraZeneca PLC - Company Statement
AstraZeneca PLC - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
AstraZeneca PLC - Key Manufacturing Facilities
Section 2 – Company Analysis
AstraZeneca PLC - Business Description
AstraZeneca PLC - Corporate Strategy
AstraZeneca PLC - SWOT Analysis
SWOT Analysis - Overview
AstraZeneca PLC - Strengths
Strength - Widespread Geographical Presence
Strength - Diversified Product Portfolio
Strength - Focused Research and Development Capabilities
AstraZeneca PLC - Weaknesses
Weakness - Litigation Claims
Weakness - Discontinuations/Terminations
Weakness - Declined Operational Performance
AstraZeneca PLC - Opportunities
Opportunity - Regulatory Approvals and New Product Launches
Opportunity - Strategic Agreements
Opportunity - Market Potential: Cancer
Opportunity - Significant Acquisitions and Divestitures
AstraZeneca PLC - Threats
Threat - Competitive Pressures from Generic Manufacturers
Threat - Uncertain R&D Outcomes
Threat - Stringent Government Regulations
AstraZeneca PLC - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
AstraZeneca PLC, Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
AstraZeneca PLC, Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014
AstraZeneca PLC, Recent Deals Summary
Section 5 – Company’s Recent Developments
AstraZeneca PLC, Recent Developments
Apr 07, 2014: Starpharma expands its Drug Delivery Program with AstraZeneca
Mar 31, 2014: AstraZeneca and MRC enter strategic collaboration to create new centre for early drug discovery in Cambridge, UK
Mar 28, 2014: Pfizer Statement on U.S. FDA Approval of Over-the-Counter Nexium 24HR
Mar 13, 2014: Medimmune, MD Anderson Join Forces to Advance Cancer Immunotherapy
Mar 11, 2014: AstraZeneca announces sale of Alderley Park site in Cheshire, UK
Mar 07, 2014: Astrazeneca Says Nexium Safe With Product From Ranbaxy
Feb 20, 2014: AstraZeneca Patient Assistance Programs Provided More Than Half a Million Patients with Free Medicine in 2013
Feb 20, 2014: CAS and AstraZeneca Agree to Five-Year SciFinder Contract
Feb 11, 2014: FDA Requests Clinical Trials Data Related To AstraZeneca’s Saxagliptin
Feb 06, 2014: Astrazeneca Announces More Job Reductions In UK
Section 6 – Appendix
Methodology
Ratio Definitions
About Us
Contact Us
Disclaimer

List of Tables
AstraZeneca PLC, Key Facts
AstraZeneca PLC, Key Employees
AstraZeneca PLC, Key Employee Biographies
AstraZeneca PLC, Major Products and Services
AstraZeneca PLC, Number of Pipeline Products by Therapy Area
AstraZeneca PLC, Number of Pipeline Products by Development Stage
AstraZeneca PLC, Pipeline Products By Therapy Area and Development Phase
AstraZeneca PLC, History
AstraZeneca PLC, Subsidiaries
AstraZeneca PLC, Key Manufacturing Facilities
AstraZeneca PLC, Key Competitors
AstraZeneca PLC, Ratios based on current share price
AstraZeneca PLC, Annual Ratios
AstraZeneca PLC, Interim Ratios
AstraZeneca PLC, Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
AstraZeneca PLC, Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014
AstraZeneca PLC, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
AstraZeneca PLC, Pipeline Products by Therapy Area
AstraZeneca PLC, Pipeline Products by Development Phase
AstraZeneca PLC, Performance Chart (2009 - 2013)
AstraZeneca PLC, Ratio Charts
AstraZeneca PLC, Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
AstraZeneca PLC, Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014
 
Companies Mentioned
Pfizer Inc.
Abbott Laboratories
Consort Medical plc
Novartis AG
C. R. Bard, Inc.
3M Health Care
GlaxoSmithKline plc
Boehringer Ingelheim GmbH
 
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/1314893

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Page 1 of 2
Printed Aug 23th 2014
9:37:23 PM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

AstraZeneca PLC (AZN) - Financial and Strategic SWOT Analysis Review

Web Address

http://www.researchandmarkets.com/reports/1314893

Office Code

OCGOOGLE

 

Report Formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User USD 125
Electronic (PDF) - Site License USD 250
Electronic (PDF) - Enterprisewide USD 375

Contact information

Please enter all the information below in block capitals.

Title:
Mr Mrs Dr Miss Ms Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed Aug 23th 2014
9:37:23 PM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
 
Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Pay by Wire Transfer:

Please transfer funds to:

Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
 

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)